BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 19937994)

  • 1. Preoperative tumor marker doubling time is a useful predictor of recurrence and prognosis after hepatic resection of hepatocellular carcinoma.
    Masuda T; Beppu T; Horino K; Komori H; Hayashi H; Okabe H; Otao R; Horlad H; Ishiko T; Takamori H; Kikuchi K; Baba H
    J Surg Oncol; 2010 Oct; 102(5):490-6. PubMed ID: 19937994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological risk factors for recurrence within one year after initial hepatectomy for hepatocellular carcinoma.
    Hayashi M; Shimizu T; Hirokawa F; Inoue Y; Komeda K; Asakuma M; Miyamoto Y; Takeshita A; Shibayama Y; Tanigawa N
    Am Surg; 2011 May; 77(5):572-8. PubMed ID: 21679590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are both PIVKA-II and alpha-fetoprotein necessary in follow-up management after hepatic resection for hepatocellular carcinoma?
    Koh T; Taniguchi H; Katoh H; Kunishima S; Yamaguchi A; Yamagishi H
    Hepatogastroenterology; 2002; 49(48):1615-8. PubMed ID: 12397748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
    Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
    Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
    Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
    Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
    Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC.
    Toyoda H; Kumada T; Kaneoka Y; Osaki Y; Kimura T; Arimoto A; Oka H; Yamazaki O; Manabe T; Urano F; Chung H; Kudo M; Matsunaga T
    J Hepatol; 2008 Aug; 49(2):223-32. PubMed ID: 18571271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma.
    Kaibori M; Ishizaki M; Matsui K; Kwon AH
    J Surg Oncol; 2010 Oct; 102(5):462-8. PubMed ID: 20872949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
    Kim MJ; Bae KW; Seo PJ; Jeong IK; Kim JH; Lee BH; Bang KT; Kim DW; Song IH
    Korean J Hepatol; 2006 Sep; 12(3):404-11. PubMed ID: 16998292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NX-PVKA levels before and after hepatectomy of hepatocellular carcinoma as predictors of patient survival: a preliminary evaluation of an improved assay for PIVKA-II.
    Nanashima A; Abo T; Taura N; Shibata H; Ichikawa T; Takagi K; Arai J; Oyama S; Nagayasu T
    Anticancer Res; 2013 Jun; 33(6):2689-97. PubMed ID: 23749928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma.
    Kim J; Ki SS; Lee SD; Han CJ; Kim YC; Park SH; Cho SY; Hong YJ; Park HY; Lee M; Jung HH; Lee KH; Jeong SH
    Am J Gastroenterol; 2006 Sep; 101(9):2051-9. PubMed ID: 16848813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy.
    Takahashi S; Kudo M; Chung H; Inoue T; Ishikawa E; Kitai S; Tatsumi C; Ueda T; Nagai T; Minami Y; Ueshima K
    Oncology; 2008; 75 Suppl 1():91-8. PubMed ID: 19092277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP.
    Baek YH; Lee JH; Jang JS; Lee SW; Han JY; Jeong JS; Choi JC; Kim HY; Han SY
    Hepatogastroenterology; 2009; 56(91-92):763-7. PubMed ID: 19621698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
    Fujiyama S; Morishita T; Shibata J; Sato T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma.
    Fujioka M; Nakashima Y; Nakashima O; Kojiro M
    Hepatology; 2001 Dec; 34(6):1128-34. PubMed ID: 11732002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the presence of circulating hepatocellular carcinoma cells indicate a risk of recurrence after resection?
    Jeng KS; Sheen IS; Tsai YC
    Am J Gastroenterol; 2004 Aug; 99(8):1503-9. PubMed ID: 15307868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of a combination of pre- and post-treatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomy.
    Toyoda H; Kumada T; Tada T; Niinomi T; Ito T; Kaneoka Y; Maeda A
    J Hepatol; 2012 Dec; 57(6):1251-7. PubMed ID: 22824818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and a monitor of recurrence of hepatocellular carcinoma after curative liver resection.
    Zhang XF; Lai EC; Kang XY; Qian HH; Zhou YM; Shi LH; Shen F; Yang YF; Zhang Y; Lau WY; Wu MC; Yin ZF
    Ann Surg Oncol; 2011 Aug; 18(8):2218-23. PubMed ID: 21336512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
    Fujiyama S; Morishita T; Sagara K; Sato T; Motohara K; Matsuda I
    Hepatogastroenterology; 1986 Oct; 33(5):201-5. PubMed ID: 2433199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.